KAISER PERMANENTE®

Infliximab-dyyb (INFLECTRA) – Maintenance Infusion Therapy Plan Orders

Page 1 of 3

Instructions to Provider

Review orders and note any changes. All orders with \square will be placed unless otherwise noted. Please fax completed order form to the infusion center where the patient will be receiving treatment (see fax numbers at the end of this protocol). Lab orders are not included on this form – place orders via usual method. Lab monitoring is the responsibility of the ordering physician.

Please complete all of the following:				
□ Pre-Service Authorization has been obtained by Kaiser Permanente Fax: 1-888-282-2685 Voice : 1-800-289-1363				
Order Date:	Diagnosis: ICD-10 code (REQUIRED):			
Weight:kg	ICD-10 description			
General Plan Communication				
Special instructions/notes:				
Provider Information				
 Live vaccines should not be given concurrently. Do not combine with tumor necrosis factor (TNF) agents or other biologic DMARDs. 				
Infusion Therapy				
✓ infliximab-dyyb (INFLECTRA) in 0.9% sodium chloride IV infusion (250 mL or 500 mL; max				
concentration 4 mg/ml) Dose: □ 3 mg/kg □ 5 mg/kg □ mg/kg x weight (kg) = Total Dose (will be rounded the nearest 100 mg)				
	🗆 400 mg 🛛 500 mg 🗆 600 mg 🖓 700 mg 🖓 mg			
Route: Intravenous				
Frequency: Every weeks Infusion Rate: 10 – 1,100 mL/hr titrate	ed.			
250 mL bag: Start infusion rate at 10 mL/hr for 15 minutes, then increase to 20 mL/hr for 15				
minutes, then 40 mL/hr for 15 minutes, then 80 mL/hr for 15 minutes, then 150 mL/hr for 15 minutes, then 250 mL/hr until infusion complete.				
500 mL bag: Start infusion rate at 20 mL/hr for 15 minutes, then increase to 40 mL/hr for 15				
minutes, then 80 mL/hr for 15 minutes, then 160 mL/hr for 15 minutes, then 300 mL/hr for 15				
minutes, then 500 mL/hr until infusion complete.				
<u>60 min Rapid Infusion Rate</u> : Infuse over 60 min at a rate up to 550 mL/hr, depending on volume of bag. May be				
infused over 60 min if patient agrees and received at least 4 consecutive infliximab (or biosimilar) infusions over 2 hours with no evidence of infusion reaction. Document qualifications prior to				
administration of 60 min rapid infusion.				
<u>30 min Rapid Infusion Rate</u> : Infuse over 30 min at a rate up to 1,100 mL/hr, depending on volume of bag. May				
be infused over 30 min if patient agrees and received at least 4 consecutive infliximab (or biosimilar) infusions over 1 hour with no evidence of infusion reaction. Document qualifications				
prior to administration of 30 min rapid infusion.				
If infusion-related reaction:				
1) STOP infusion immediately; 2) Increase primary infusion to wide open rate; 3) Administer PRN medications				
per hypersensitivity protocol; 4) Notify MD				
Note any changes to above regimen:				
Provider Signature:	Date:			
Printed Name:	Phone: Fax:			

нім

Revision Date: 11/16/2022 Kaiser Permanente <Reference#115102>

Name: ___

Kaiser Permanente Member I.D. # _

Date of Birth ____



Infliximab-dyyb (INFLECTRA) – Maintenance Infusion Therapy Plan Orders

Page 2 of 3

Name:	
iname.	

Kaiser Permanente Member I.D. # ____

Date of Birth ____

Pre-N						
V	acetaminophen (TYLENOL) tablet <i>Dose:</i> 650 mg <i>Route:</i> Oral <i>Frequency:</i> Once PRN, 30 minutes prior to infliximab-dyyb infusion (if not taken at home). May also be given once as needed during infusion for achiness, headache, or fever if not given prior to infusion					
\checkmark	to infusion. cetirizine (ZYRTEC) tablet					
V	<i>Dose:</i> 10 mg <i>Route:</i> Oral <i>Frequency:</i> Once PRN, at least 30 minutes prior to infliximab-dyyb infusion (if not taken at home).					
V						
	 Dose: Route: Oral Frequency: Once, 30 minutes prior to infliximab-dyyb infusion No routine pre-medications necessary. Above pre-meds may be given if patient has reaction and requires pre-medications for future doses. 					
IV Lin	e Care					
V	0.9% sodium chloride infusion 250 mL <i>Rate:</i> 30 mL/hr <i>Route:</i> Intravenous Start peripheral IV if no central line					
	on Reaction Meds					
\checkmark	albuterol (PROVENTIL) nebulizer solution 0.083% Dose: 2.5 mg Route: Nebulization Frequency: PRN for shortness of breath/wheezing					
\checkmark	diphenhydrAMINE (BENADRYL) injectable					
	Dose: 25 mg Route: Intravenous Frequency: Once PRN, May repeat x1 for urticaria, pruritus,					
	shortness of breath. May repeat in 15 minutes if symptoms not resolved.					
<u>N</u>	 Dose: 0.3 mg Route: Intramuscular Frequency: Once PRN for anaphylaxis. Inject into lateral thigh and hold for 10 seconds. Massage the injected area. Use for patients weighing greater than 27.3 kg (60 lbs). Use amp and 1.5 inch needle for patients with BMI greater than 30. Notify physician if administered. MethylPREDNISolone Sod Succ (PF) Inj 125 mg (SOLU-Medrol PF). 					
<u> </u>	Dose : 125 mg Route : IV push Frequency: Once PRN for hypersensitivity reaction. Notify MD if administered.					
	Review for Nursing					
 GI/Derm/Rheumatology Indications (when labs available in Epic): Ensure CBC, ALT, AST, and Creatinine have been drawn within the last 16 weeks. 						
 If labs have not been drawn within 16 weeks, proceed with infusion and instruct patient to receive lab draw today. If patient has not had labs drawn within 20 weeks, hold infusion and notify provider. 						
Nursi	ng Orders					
 Do not administer infliximab-dyyb and notify provider if patient has a temperature greater than 100 degrees F, complains of symptoms of acute viral or bacterial illness, or if patient is taking antibiotics for current infection. Document protocol qualifications in the Therapy Plan if patient will receive rapid infliximab-dyyb infusion. Administer using a low protein-binding 0.2 micron filter. Post infusion observation time per Nursing Standard or as follows: at least 30 minutes for the first 4 infusions, 1-hour for the first rapid 60 min and first rapid 30 min infusion, and per nurse discretion for subsequent infusions. Discontinue IV line when therapy complete and patient stabilized. 						
References						
 INFLECTRA[®] Prescribing Information. Revised June 2021. 						
Provi	der Signature: Date:					

НІМ

Printed Name: _____

Revision Date: 11/16/2022 Kaiser Permanente <Reference#115102>

Phone: _____ Fax: _____

Infliximab-dyyb (INFLECTRA) – Maintenance

Infusion Therapy Plan Orders

Page 3 of 3

Kaiser Permanente Infusion Locations

Bellevue Medical Center 11511 NE 10th St, Bellevue, WA 98004 Phone: 425-502-3820 Fax: 425-502-3811 **Capitol Hill Medical Center** 201 16th Ave E, Seattle WA 98112 Fax: 206-326-3624 Phone: 206-326-3180 **Everett Medical Center** 2930 Maple St, Everett, WA 98201 Fax: 425-261-1578 Phone: 425-261-1566 **Olympia Medical Center** 700 Lilly Road N.E., Olympia, WA 98506 Fax: 360-923-7609 Phone: 360-923-7600 Riverfront Medical Center – Spokane W 322 North River Drive, Spokane, WA 99201 Fax: 509-434-3184 Phone: 509-324-6464 Silverdale Medical Center 10452 Silverdale Way NW, Silverdale, WA 98383 Fax: 360-307-7421 Phone: 360-307-7316 Tacoma Medical Center 209 Martin Luther King Jr Way, Tacoma, WA 98405 Fax: 253-596-3351 Phone: 253-596-3350

Provider Signature:		Date:	
Printed Name:	Phone:	Fax:	
	HIM Revision Da	ate: 11/16/2022 Kaiser Permanente <reference#115102></reference#115102>	